UMB Data Catalog

UMB Dataset

Alternate Title(s): Efficacy of Single-Dose Live Oral Cholera Vaccine CVD 103-HgR
Authors: Wilbur H. Chen

Myron M. Levine
Description: This dataset is the result of a phase 3, randomized, double-blind, placebo-controlled efficacy trial of a single dose live oral cholera vaccine. PXVX0200 was developed to rapidly confer protection to humanitarian relief workers and other travelers visiting cholera-endemic areas as well as residents in regions experiencing outbreaks. Existing licensed vaccines require 2 or 3 (children) doses weeks apart....
Subject: Vaccines
Access Rights: Approval required

Registration required

UMB Dataset

Authors: Wilbur H. Chen
Description: This multicenter randomized, controlled, double-blind Phase 1 trial investigated the safety, tolerability, immunogenicity, and feasibility of adding an adjuvant to an influenza vaccine at point-of-use (commonly referred to as the Mix-N-Match study). Inactivated influenza A/Indonesia/05/2005 virus vaccine and the adjuvant, AS03, were provided by the US Department of Health and Human Services (HHS) Biomedical...
Subject: Vaccines
Timeframe: 2011
Access Rights: Registration required

UMB Dataset

Authors: Wilbur H. Chen
Description: The research associated with this dataset is an extension of a multicenter randomized, controlled, double-blind phase 1 trial that investigated combining an adjuvant (AS03) with an influenza (A/H5N1) vaccine at point-of-use (see “Related Datasets” below). In the original study adult volunteers were given 2 intramuscular doses of vaccine containing 3.75, 7.5, or 15 mcg of hemagglutinin (HA) with or...
Subject: Vaccines
Access Rights: Registration required

UMB Dataset

Description: Non-typhoidal Salmonella (NTS) is responsible for approximately 93 million cases of gastroenteritis annually. Little research has been directed towards a development of vaccines against Salmonella serogroups O:6,7 or O:8. Researchers constructed a live attenuated serogroup O:8 vaccine, CVS 1979, by deleting guaBA, htrA, and aroA from the genome of S. Newport. Over the course of 6 weeks, 6 to 8-week-old...
Subject: Salmonella Vaccines

Vaccine Development
Access Rights: Unrestricted access

UMB Dataset

Authors: Joseph Fraiman

Juan Erviti

Mark Jones

Sander Greenland

3 more author(s)...
Description: An adapted version of the Brighton Collaboration priority list was used to evaluate serious adverse events (SAE) of special interest observed in mRNA Covid-19 vaccine trials. In December of 2020, reviewers searched journal publications and trial data on the FDA’s and Health Canada’s websites to locate SAE results tables for these trials. For each trial, blinded SAE tables were prepared. Using these...
Subject: COVID-19/prevention & control

Vaccines
Timeframe: 2020
Access Rights: Unrestricted access

UMB Dataset

Authors: Etsuro Nanishi

Marisa E. McGrath

Timothy R. O’Meara

Soumik Barman

17 more author(s)...
Description: This study investigates multiple vaccine strategies to enhance immunogenicity and protection against SARS-CoV-2 in aged mice. The study aims to determine the effect of a booster dose, with an emphasis on older age. Female three and eleven-month-old BALB/c mice were studied over the course of 38 weeks. Mice received BNT162b2 SARS-CoV-2 spike mRNA vaccine series, primary vaccination series, and mock...
Subject: COVID-19/prevention & control

Viral Vaccines/genetics
Access Rights: Unrestricted access
Local Experts: Matthew B. Frieman

UMB Dataset

Authors: Seyed M. Moghadas

Thomas N. Vilches

Kevin Zhang

Shokoofeh Nourbakhsh

3 more author(s)...
Description: Due to constraints in vaccine supply, this agent-based model of COVID-19 transmission was developed to compare the impact of two vaccination strategies: 1) vaccinate more individuals with the first dose of available vaccines and delay the second dose or 2) to continue with the recommended 2-dose series as tested in clinical trials. Model population was stratified into 6 age groups of 0 to 4, 5 to 19,...
Subject: COVID-19 Vaccines/administration & dosage

COVID-19/prevention & control

SARS-CoV-2/immunology
Access Rights: Unrestricted access
Local Experts: Meagan C. Fitzpatrick